Home › Research › Biomarkers
Optimizing Plasma p-tau217 Thresholds for Detection of Preclinical Alzheimer’s Disease Across Different Racial and Ethnic Backgrounds (P10-13.011)
Yoav D. Piura, Christian Lachner, Alicia Algeciras‐Schimnich, Daniel J. Figdore, Joshua A. Bornhorst, Ronald Petersen, Clifford Jack, Paula A. Aduen et al.. Neurology, 2026-06-09
Topic: Amyloid, tau and blood-test diagnosis
To evaluate plasma p-tau217 ability to detect pre-symptomatic Alzheimer disease (AD) in ethnoracially diverse cognitively normal individuals.
Key findings
- To evaluate plasma p-tau217 ability to detect pre-symptomatic Alzheimer disease (AD) in ethnoracially diverse cognitively normal individuals.
Why it matters
This entry only states the objective of evaluating plasma p-tau217 for detecting pre-symptomatic Alzheimer's disease in ethnoracially diverse cognitively normal individuals. No results or conclusions are provided, so no impact on treating, curing or preventing Alzheimer's can be stated.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 33/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 32 of the 96 points we could judge it on, which is 33 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Gregory Day holds only 4 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 2 / 3 | Mayo Clinic: institution h-index 1,606 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 32 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 32 of the 96 points we could judge it on is 33 out of 100. |
| Total | 33 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Piura, Y. D., Lachner, C., Algeciras‐Schimnich, A., Figdore, D. J., Bornhorst, J. A., Petersen, R., et al. (2026). Optimizing Plasma p-tau217 Thresholds for Detection of Preclinical Alzheimer’s Disease Across Different Racial and Ethnic Backgrounds (P10-13.011). Neurology. https://doi.org/10.1212/wnl.0000000000215003
Vancouver
Piura YD, Lachner C, Algeciras‐Schimnich A, Figdore DJ, Bornhorst JA, Petersen R, et al. Optimizing Plasma p-tau217 Thresholds for Detection of Preclinical Alzheimer’s Disease Across Different Racial and Ethnic Backgrounds (P10-13.011). Neurology. 2026. doi:10.1212/wnl.0000000000215003.
BibTeX
@article{piura2026-c5d27418,
author = {Piura, Yoav D. and Lachner, Christian and Algeciras‐Schimnich, Alicia and Figdore, Daniel J. and Bornhorst, Joshua A. and Petersen, Ronald and Jack, Clifford and Aduen, Paula A. and others},
title = {{Optimizing Plasma p-tau217 Thresholds for Detection of Preclinical Alzheimer’s Disease Across Different Racial and Ethnic Backgrounds (P10-13.011)}},
journal = {Neurology},
year = {2026},
doi = {10.1212/wnl.0000000000215003},
url = {https://doi.org/10.1212/wnl.0000000000215003}
}
Related studies in Biomarkers
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.